Mizuho Securities’s Seres Therapeutics MCRB Stock Holding History

Mizuho Securities’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-110	Closed	-$7K	–	154
2019 Q2	$7K	Buy	+110	New	+$10.4K	0.01%	140

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mizuho Securities's MCRB Position: Q3 2019 in Review

Mizuho Securities sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 110 shares — an estimated $7K sold.

Mizuho Securities first reported a position in MCRB in Q2 2019 and held it in 1 quarter. The position peaked at $7K in Q2 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

Mizuho Securities reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
Mizuho Securities sold 110 Seres Therapeutics shares in Q3 2019, an estimated $7K.
Mizuho Securities first reported a position in Seres Therapeutics in Q2 2019 and held it in 1 quarter.
Mizuho Securities's Seres Therapeutics position peaked at $7K in Q2 2019.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Mizuho Securities's 13F filing for Q3 2019, filed 14 Nov 2019.